Krystal Biotech Inc (KRYS)

Fixed asset turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue (ttm)	US$ in thousands	293,354	247,796	172,511	103,808	58,154	10,946	2,390	809	0	0	0	0	0	0	0	0	0	0	0	542
Property, plant and equipment	US$ in thousands	155,168	156,592	158,808	160,011	161,202	164,029	163,737	163,073	161,684	157,786	151,214	136,927	112,355	78,642	44,972	33,883	30,876	17,512	13,215	10,264
Fixed asset turnover		1.89	1.58	1.09	0.65	0.36	0.07	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.05

December 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $293,354K ÷ $155,168K
= 1.89

The fixed asset turnover ratio for Krystal Biotech Inc has shown a significant improvement over the past several quarters. The ratio was notably low at 0.05 as of March 31, 2020, and remained at 0.00 for the subsequent three quarters. However, there has been a notable increase in the ratio starting from the June 30, 2023, quarter where it improved to 0.01.

The trend of improvement continued in the following quarters, with the fixed asset turnover ratio reaching 1.89 as of December 31, 2024. This indicates that the company is generating more revenue relative to its fixed assets, reflecting increased efficiency in asset utilization.

The substantial increase in the fixed asset turnover ratio suggests that Krystal Biotech Inc is effectively utilizing its fixed assets to generate sales and improve overall operational performance. This positive trend may signify enhanced efficiency in production processes and could potentially lead to improved profitability in the future.